Dropbox: The Inside Story Of Tech’s Hottest Startup
[Not single-page] Jobs smiled warmly as he told them he was going after their market. “He said we were a feature, not a product,” says Houston. Courteously, Jobs spent the next half hour waxing on over tea about his return to Apple, and why not to trust investors, as the duo—or more accurately, Houston, who plays Penn to Ferdowsi’s mute Teller—peppered him with questions.
When Jobs later followed up with a suggestion to meet at Dropbox’s San Francisco office, Houston proposed that they instead meet in Silicon Valley. “Why let the enemy get a taste?” he now shrugs cockily. Instead, Jobs went dark on the subject, resurfacing only this June, at his final keynote speech, where he unveiled iCloud, and specifically knocked Dropbox as a half-attempt to solve the Internet’s messiest dilemma: How do you get all your files, from all your devices, into one place?
Houston’s reaction was less cocky: “Oh, s–t.”
Clayton Christensen: The Survivor
The Harvard Business School professor’s work took on new urgency the past few years as he suffered a heart attack followed by cancer followed by a stroke. For Christensen it was not a reason to get too upset. It was another opportunity, in a lifetime full of them, to gain insight into how to make the world work better. Because of his July stroke it took a long time for Christensen to be ready to sit down with Forbes. He was in intensive speech therapy, eight hours a day at the beginning. But he graciously agreed to tell his inspiring story in January, the same month he went back to teaching. Here it is in his words, along with those of his family, friends and close colleagues.
The Gene Machine: Building the Personal DNA Decoder
Have we mentioned the ifs? Like all potentially disruptive innovations, gene sequencers could fizzle. Their success depends on unpredictable events: how fast the technology improves, how quickly researchers can make medical discoveries based on the new machines and–most critically–whether drugs can be developed to treat diseases. Gene test prices could drop, becoming a low-margin commodity like medical blood tests (cholesterol, blood sugar and so on), which, at a few bucks a pop, are a $40 billion business. Ultimately Rothberg’s machine may not win. Like the Commodore 64 home computer that dominated in the 1980s and disappeared soon after, the PGM could be quickly eclipsed.